Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07134101) titled 'Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMATRTi-RC01)' on Aug. 11.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: The First Affiliated Hospital with Nanjing Medical University

Condition: Colorectal Cancer (Diagnosis)

Intervention: Drug: Serplulimab Drug: Bevacizumab Radiation: Short-Course Radioterapy

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: September 1, 2025

Target Sample Size: 138

To know more, visit https://clinical...